Botulinum Toxin Product 'Letybo' to Enter U.S. Market
Kim SangJin
letyou@alphabiz.co.kr | 2024-07-31 05:47:24
(Photo = hugel)
[Alpha Biz= Reporter Kim Sangjin] Hugel announced on the 30th that it has shipped the first batch of its botulinum toxin product Letybo (known as Botulax in Korea) to the U.S. Hugel received FDA approval for Letybo in 50-unit and 100-unit formulations earlier this year, and this export marks the beginning of its entry into the U.S. market.
To ensure a successful market entry, Hugel plans to leverage its partnership with U.S. distributor BENEV for distribution and marketing. Hugel will use BENEV's established sales network to distribute Letybo and will also conduct academic marketing and educational activities targeting medical professionals to communicate the safety and efficacy of the product.
[ⓒ AlphaBIZ. 무단전재-재배포 금지]
많이 본 기사
- 1AMD’s Lisa Su Forges Broad Semiconductor Alliance with Samsung Electronics and Naver in Korea
- 2Trial to Begin in NPS Lawsuit Against Samsung Over 2015 Merger
- 3Kyobo Life Enters Savings Bank Sector After Securing Approval to Acquire SBI Savings Bank
- 4SEC Reclassifies Major Cryptocurrencies as Digital Commodities, Signaling Regulatory Shift
- 5LPG Shortage Deepens in India Amid Hormuz Disruption, Triggering Theft and Cooking Fuel Shift
- 6Korea Exchange Pledges Process Overhaul and Accountability After SCM Life Science Listing Error